

**CytomX Therapeutics, Inc.  
151 Oyster Point Blvd., Suite 400  
South San Francisco, CA 94080**

August 15, 2024

**VIA EDGAR**

Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, DC 20549

Attention: Tamika Sheppard

**Re: CytomX Therapeutics, Inc.  
Registration Statement on Form S-3 (Registration No. 333-281433)**

Ladies and Gentlemen:

In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration by the Securities and Exchange Commission of the effective date of the above-referenced Registration Statement on Form S-3 (the "Registration Statement") of CytomX Therapeutics, Inc. We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on August 19, 2024, or as soon as practicable thereafter.

Thank you for your assistance in this matter.

---

Very truly yours,

**CytomX Therapeutics, Inc.**

By: /s/ Lloyd A. Rowland

\_\_\_\_\_  
Lloyd A. Rowland

Senior Vice President and General Counsel

CC: Sean A. McCarthy, CytomX Therapeutics, Inc.  
Chris Ogden, CytomX Therapeutics, Inc.  
Mark V. Roeder, Latham & Watkins LLP

*[Signature Page to CytomX Therapeutics, Inc. Acceleration Letter]*